ArticleCellular and molecular life sciences : CMLS2025
Intracellular IL-24 ameliorates lipid metabolic disorders in metabolic dysfunction-associated steatohepatitis by restoring the autophagy-lysosome pathway.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Autophagy in MASLD: A Metabolic and Precision Medicine Perspective.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Lipophagy in disease: signaling control, organelle communication, and therapeutic opportunities.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatohepatitis (MASH) is associated with impaired hepatic autophagy, but its key regulators remain unclear. This study delineates IL-24 as a regulator of autophagy in MASH.
methodsIL-24 was identified via bioinformatics in patient datasets and validated in metabolic dysfunction-associated steatotic liver disease (MASLD) patient sera. A high-fat high-fructose diet (HFFD) induced MASH in mice, with IL-24 overexpression via adeno-associated virus. Functional assessments were performed both in vivo and in primary hepatocytes using immunohistochemistry, Western blot, immunofluorescence, dual-fluorescence autophagic flux tracking, and multi-omics analyses.
resultsMASLD patients and animal models showed significantly lower IL-24 expression, with levels inversely related to disease severity. IL-24 intervention improved liver steatosis, inflammation, fibrosis, and insulin resistance in MASH mice. Mechanistically, IL-24 mediates hepatocyte autophagy and alleviates lipid accumulation through the IL-22R1/IL-20R2 receptor complex. It activated AMP-activated protein kinase (AMPK), suppressed mechanistic target of rapamycin (mTOR), enhanced transcription factor EB (TFEB) nuclear translocation (as evidenced by reduced microtubule-associated protein 1 A/1B-light chain 3-II/sequestosome 1), restored autophagy-lysosome function, and increased lipid degradation. Multi-omics analysis indicated increased fatty acid oxidation and decreased glucose metabolism. Notably, KEGG enrichment analysis revealed significant association of differential metabolites with autophagy-related pathways, corroborating findings from transcriptomics and the AMPK/mTOR/TFEB regulatory axis.
conclusionIL-24 preferentially utilizes the IL-22R1/IL-20R2 receptor complex to modulate the AMPK/mTOR/TFEB axis, thereby inducing autophagic-lysosomal activation, regulating glucose and lipid metabolism, and ameliorating hepatic lipid accumulation in MASH. These findings highlight IL-24 as a novel therapeutic target for MASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.